CONDUIT PHARMACEUTICAL

Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline

04 Nov 2024 06:30:00 By Nasdaq GlobeNewswire

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

01 Nov 2024 15:45:00 By Nasdaq GlobeNewswire

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

12 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

08 Aug 2024 05:30:00 By Nasdaq GlobeNewswire

Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

16 Jul 2024 06:30:00 By Nasdaq GlobeNewswire

Conduit Pharmaceuticals to Join Russell 3000® Index

13 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

19 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub

11 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

31 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference

02 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656

11 Oct 2023 07:30:00 By Nasdaq GlobeNewswire